Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, September 22, 2017
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
[ Fri, Sep 22nd 2017
] - WOPRAI
Thu, September 21, 2017
[ Thu, Sep 21st 2017
] - WOPRAI
[ Thu, Sep 21st 2017
] - WOPRAI
[ Thu, Sep 21st 2017
] - WOPRAI
[ Thu, Sep 21st 2017
] - WOPRAI
[ Thu, Sep 21st 2017
] - WOPRAI
Paul Matteis Maintained (ALNY) at Hold with Increased Target to $112 on, Sep 21st, 2017
Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $72 to $112 on, Sep 21st, 2017.
Paul has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $99 on, Friday, September 8th, 2017
Similar Stocks and Investing Articles
[ Fri, Sep 15th 2017
] - WOPRAI
[ Tue, May 03rd 2016
] - WOPRAI
[ Mon, Apr 04th 2016
] - WOPRAI
[ Fri, Mar 11th 2016
] - WOPRAI
[ Wed, Oct 21st 2015
] - WOPRAI
[ Mon, Oct 19th 2015
] - WOPRAI
[ Mon, Oct 19th 2015
] - WOPRAI
[ Mon, Oct 19th 2015
] - WOPRAI
[ Wed, Oct 14th 2015
] - WOPRAI
[ Mon, Aug 31st 2015
] - WOPRAI